The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery

References

• Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113(2):315–325
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010;2(2):68–75
   PubMed Web of Science ®Google Scholar
• Baumgartner JM, Ahrendt SA, Pingpank JF, et al. Aggressive locoregional management of recurrent peritoneal sarcomatosis. J Surg Oncol. 2013;107(4):329–334
   Google Scholar
• Alexander HRJr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779–786
   PubMed Web of Science ®Google Scholar
• Takemoto M, Kuroda M, Urano M, et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumors. Int J Hyperthermia. 2003;19(2):193–203
   PubMed Web of Science ®Google Scholar
• Cavaliere F, Giannarelli D, Valle M, et al. Peritoneal carcinomatosis from ovarian epithelial primary: Combined aggressive treatment. In vivo. 2009;23(3):441–446
   Google Scholar
• Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surgical Oncol. 2009;100(4):331–334
   Google Scholar
• Cashin PH, Ehrsson H, Wallin I, Nygren P, Mahteme H. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol. 2013;69(3):533–540
   PubMed Web of Science ®Google Scholar
• Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007;93(2):138–144
   Google Scholar
• Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32(6):671–675
   Google Scholar
• Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004;28:1040–1045
   PubMed Web of Science ®Google Scholar
• Hadi R, Saunders V, Utkina O, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg. 2006;76:156–161
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490–2518
   PubMed Web of Science ®Google Scholar
• Saif MW. Management of hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol. 2008;6(5):243–248
   PubMedGoogle Scholar
• Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure – Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204–R212
   PubMed Web of Science ®Google Scholar
• Klahr S, Miller SB. Acute oliguria. N Engl J Med. 1998;338(10):671–675
   PubMed Web of Science ®Google Scholar
• Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol. 2005;56(5):535–542
   Google Scholar
• Sahai SK, Zalpour A, Rozner MA. Preoperative evaluation of the oncology patient. Med Clin North Am. 2010;94(2):403–419
   Google Scholar
• Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24(1):19–38
   PubMed Web of Science ®Google Scholar
• Ivanov AI, Christodoulou J, Parkinson JA, et al. Cisplatin binding sites on human albumin. J Biol Chem. 1998;273(24):14721–14730
   PubMed Web of Science ®Google Scholar
• Lau AH. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int. 1999;56(4):1295–1298
   Google Scholar
• Giroux L, Bettez P, Giroux L. Mitomycin-C nephrotoxicity: A clinico-pathologic study of 17 cases. Am J Kidney Dis. 1985;6(1):28–39
   Google Scholar
• Baratti D, Kusamura S, Mingrone E, Balestra MR, Laterza B, Deraco M. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2012;256(2):334–341
   Google Scholar
• Javier M, Loarte A, Pilco P. [Nutritional evaluation in patients with total and partial gastrectomy for gastric adenocarcinoma]. Rev Gastroenteroll Peru. 2008;28(3):239–243
   Google Scholar
• Deegan PM, Nolan C, Ryan MP, et al. The role of the renin-angiotensin system in cisplatin nephrotoxicity. Renal Fail. 1995;17(6):665–674
   PubMed Web of Science ®Google Scholar
• Haghighi M, Nematbakhsh M, Talebi A, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: Gender-related differences. Ren Fail. 2012;34(8):1046–1051
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293–308
   PubMed Web of Science ®Google Scholar
• Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 2008;17(3):266–270
   Web of Science ®Google Scholar
• Schwarz RE, Nevarez KZ. Hypomagnesemia after major abdominal operations in cancer patients: Clinical implications. Arch Med Res. 2005;36(1):36–41
   Google Scholar